A Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of the Oral Contraceptive YAZ (20 microg Ethinylestradiol, 3mg Drospirenone) for 13 Cycles in 670 Healthy Chinese Female Volunteers.
Phase of Trial: Phase III
Latest Information Update: 10 Feb 2012
At a glance
- Drugs Drospirenone/ethinylestradiol (Primary)
- Indications Pregnancy
- Focus Therapeutic Use
- 23 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Dec 2009 Planned number of patients changed from 850 to 670 as reported by ClinicalTrials.gov.